Association of HLA-G promoter and 14-bp insertion-deletion variants with acute allograft rejection and end-stage renal disease

Tissue Antigens

Volumn 82, Issue 5, 2013, Pages 317-326

  Misra, M K ^a,b   Prakash, S ^a   Kapoor, R ^a   Pandey, S K ^b   Sharma, R K ^a   Agrawal, S ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b BANARAS HINDU UNIVERSITY   (India)

Author keywords

Acute allograft rejection; Cytomegalovirus infection; End stage renal disease; HLA G 14 bp insertion deletion; HLA G 5 URR; Soluble HLA G

Indexed keywords

HLA G ANTIGEN;

ACUTE GRAFT REJECTION; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMEGALOVIRUS INFECTION; FEMALE; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENOTYPE; HUMAN; INDEL MUTATION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; RISK FACTOR; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ACUTE ALLOGRAFT REJECTION; CYTOMEGALOVIRUS INFECTION; END-STAGE RENAL DISEASE; HLA-G 14-BP INSERTION/DELETION; HLA-G 5′ URR; SOLUBLE HLA-G;

ALLOGRAFTS; BASE PAIRING; CYTOMEGALOVIRUS INFECTIONS; DEMOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GRAFT REJECTION; HLA-G ANTIGENS; HUMANS; INDEL MUTATION; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; LINKAGE DISEQUILIBRIUM; MALE; PROMOTER REGIONS, GENETIC; SOLUBILITY;

EID: 84885716298     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/tan.12210     Document Type: Article

References (45)

1. Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999: 341: 1725-30.
2. Wolfe RA, Ashby VB, Milford EL et al. Unadjusted graft and patient survival at 3 months, 1 year, 3 years, 5 years, and 10 years: standard errors of the survival rates. In: OPTN/SRTR 2009 Annual Report: Summary Tables, Transplant Data 1997-2007. Table 1.13. 1999. (http://www.ustransplant.org).
3. Shiroishi M, Kuroki K, Ose T et al. Efficient leukocyte Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer. J Biol Chem 2006: 281: 10439-47.
4. Rajagopalan S, Long EO. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med 1999: 189: 1093-100.
5. Tan Z, Shon AM, Ober C. Evidence of balancing selection at the HLA-G promoter region. Hum Mol Genet 2005: 14: 3619-28.
6. Hviid TV, Rizzo R, Melchiorri L, Stignani M, Baricordi OR. Polymorphism in the 5' upstream regulatory and 3' untranslated regions of the HLA-G gene in relation to soluble HLA-G and IL-10 expression. Hum Immunol 2006: 67: 53-62.
7. Hviid TV, Hylenius S, Rorbye C, Nielsen LG. HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels. Immunogenetics 2003: 55: 63-79.
8. Harrison GA, Humphrey KE, Jakobsen IB, Cooper DW. A 14bp deletion polymorphism in the HLA-G gene. Hum Mol Genet 1993: 2: 2200.
9. Rousseau P, Le Discorde M, Mouillot G, Marcou C, Carosella ED, Moreau P. The 14bp deletion-insertion polymorphism in the 3' UT region of the HLA-G gene influences HLA-G mRNA stability. Hum Immunol 2003: 64: 1005-10.
10. Hviid TV, Rizzo R, Christiansen OB, Melchiorri L, Lindhard A, Baricordi OR. HLA-G and IL-10 in plasma in relation to HLA-G genotype and polymorphisms. Immunogenetics 2004: 56: 135-41.
11. Nicolae D, Cox NJ, Lester LA et al. Fine mapping and positional candidate studies identify HLA-G as an asthma susceptibility gene on chromosome 6p21. Am J Hum Genet 2005: 76: 349-57.
12. Auboeuf D, Honig A, Berget SM, O'Malley BW. Co-ordinate regulation of transcription and splicing by steroid receptor coregulators. Science 2002: 298: 416-9.
13. Contini P, Ghio M, Poggi A et al. Soluble HLA-A, -B, -C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 2003: 33: 125-34.
14. Bainbridge DR, Ellis SA, Sargent IL. HLA-G suppresses proliferation of CD4 (+) T-lymphocytes. J Reprod Immunol 2000: 48: 17-26.
15. Riteau B, Rouas-Freiss N, Menier C, Paul P, Dausset J, Carosella ED. HLA-G2, -G3, and -G4 isoforms expressed as non mature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J Immunol 2001: 166: 5018-26.
16. Gros F, Cabillic F, Toutirais O, Maux AL, Sebti Y, Amiot L. Soluble HLA-G molecules impair natural killer/dendritic cell cross talk via inhibition of dendritic cells. Eur J Immunol 2008: 38: 742-9.
17. Van Der Meer A, Lukassen HG, Van Cranenbroek B et al. Soluble HLA-G promotes Th1-type cytokine production by cytokine activated uterine and peripheral natural killer cells. Mol Hum Reprod 2007: 13: 123-33.
18. LeMaoult J, Zafaranloo K, Danff CL, Carosella ED. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB 2005: 19: 662-4.
19. Donadi EA, Castelli EC, Arnaiz-Villena A, Roger M, Rey D, Moreau P. Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association. Cell Mol Life Sci 2011: 68: 369-95.
20. Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008: 8: 753-60.
21. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002: 34: 1094-7.
22. Tripathi P, Abbas A, Naik S, Agrawal S. Role of 14-bp deletion in the HLA-G gene in the maintenance of pregnancy. Tissue Antigens 2004: 64: 706-10.
23. Akhter A, Das V, Naik S, Faridi RM, Pandey A, Agrawal S. Up-regulation of HLA-G in JEG-3 cells by dexamethasone and hydrocortisone. Arch Gynecol Obstet 2012: 285: 7-14.
24. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005: 21: 263-5.
25. Rouas-Freiss N, LeMaoult J, Moreau P, Dausset J, Carosella ED. HLA-G in transplantation: a relevant molecule for inhibition of graft rejection? Am J Transplant 2003: 3: 11-16.
26. Carosella ED, Moreau P, Le Maoult J, Le Discorde M, Rouas-Freiss N. HLA-G molecules: From maternal-fetal tolerance to tissue acceptance. Adv Immunol 2003: 81: 199-52.
27. Zheng XQ, Zhu F, Shi WW, Lin A, Yan WH. The HLA-G 14bp insertion/deletion polymorphism is a putative susceptible factor for active human cytomegalovirus infection in children. Tissue Antigens 2009: 74: 317-21.
28. Jin ZK, Xu CX, Tian PX et al. Impact of HLA-G 14-bp polymorphism on acute rejection and cytomegalovirus infection in kidney transplant recipients from northwestern China. Transpl Immunol 2012: 27: 69-74.
29. Crispim JC, Mendes-Junior CT, Wastowski IJ et al. Frequency of insertion/deletion polymorphism in exon 8 of HLA-G and kidney allograft outcome. Tissue Antigens 2008: 71: 35-41.
30. Ciliao Alves DC, De Oliveira Crispim JC, Castelli EC et al. Human leukocyte antigen-G 3′ untranslated region polymorphisms are associated with better kidney allograft acceptance. Hum Immunol 2012: 73: 52-9.
31. Piancatelli D, Maccarone D, Liberatore G et al. HLA-G 14-bp insertion/deletion polymorphism in kidney transplant patients with metabolic complications. Transplant Proc 2009: 41: 1187-8.
32. Aghdaie MH, Azarpira N, Kazemi K, Geramizadeh B, Darai M, Malekhoseini SA. Frequency of HLA-G exon 8 polymorphisms and kidney allograft outcome in Iranian population. Mol Biol Rep 2011: 38: 3593-7.
33. Castelli EC, Mendes-Junior CT, Veiga-Castelli LC, Roger M, Moreau P, Donadi EA. A comprehensive study of polymorphic sites along the HLA-G gene: implication for gene regulation and evolution. Mol Biol Evol 2011: 28: 3069-86.
34. Solier C, Mallet V, Lenfant F, Bertrand A, Huchenq A, Le Bouteiller P. HLA-G unique promoter region: functional implications. Immunogenetics 2001: 53: 617-25.
35. Gobin SJ, Keijsers V, Van Zutphen M, Van Den Elsen PJ. The role of enhancer A in the locus-specific transactivation of classical and nonclassical HLA class I genes by nuclear factor kappa B. J Immunol 1998: 161: 2276-83.
36. Tripathi P, Agrawal S. Non-classical HLA-G antigen and its role in the cancer progression. Cancer Invest 2006: 24: 178-86.
37. Ober C, Aldrich CL, Chervoneva I et al. Variation in the HLA-G promoter region influences miscarriage rates. Am J Hum Genet 2003: 72: 1425-35.
38. Berger DS, Hogge WA, Barmada MM, Ferrell RE. Comprehensive analysis of HLA-G: implications for recurrent spontaneous abortion. Reprod Sci 2010: 17: 331-8.
39. Veit TD, Chies JA. Tolerance versus immune response micro RNAs as important elements in the regulation of the HLA-G gene expression. Transpl Immunol 2009: 20: 229-31.
40. Castelli EC, Moreau P, Oya e Chiromatzo A et al. In silico analysis of microRNAS targeting the HLA-G 3′ untranslated region alleles and haplotypes. Hum Immunol 2009: 70: 1020-5.
41. Qiu J, Terasaki PI, Miller J, Mizutani K, Cai J, Carosella ED. Soluble HLA-G expression and renal graft acceptance. Am J Transplant 2006: 6: 2152-6.
42. Creput C, Le Friec G, Bahri R et al. Detection of HLA-G in serum and graft biopsy associated with fewer acute rejections following combined liver-kidney transplantation: possible implications for monitoring patients. Hum Immunol 2003: 64: 1033-8.
43. Wlasiuk P, Stec A, Piechnik A et al. Expression of soluble HLA-G in multiple myeloma patients and patients with renal failure. Leuk Res 2012: 36: 881-3.
44. Torres MI, Luque J, Lorite P et al. 14-Base pair polymorphism of human leukocyte antigen-G as genetic determinant in heart transplantation and cyclosporine therapy monitoring. Hum Immunol 2009: 70: 830-5.
45. Bardi R, Sfar I, Aounallah-Skhiri H et al. Soluble human leukocyte antigen-G (sHLA-G) in Tunisian kidney transplantation. Arch Inst Pasteur Tunis 2011: 88: 42-6.